Business
Annual Report & Financial Statements
Annual Report & Financial Statements.
About this update from Coiled Therapeutics Plc
[{"type":"text","content":"\n \n \n 11 May 2022\n \n \n \n \n \n Roquefort Therapeutics plc\n \n \n (\"Roquefort Therapeutics\" or the \"Company\")\n \n \n \n \n \n \n Annual Report & Financial Statements for period ended 31 December 2021\n \n \n \n Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company focused on early-stage opportunities in the medical biotechnology sector, announces its audited results for period ended 31 December 2021.\n \n \n Copies of the Annual Report and Financial Statements will be posted to shareholders and made available on the Company's website at: https://www.roquefortplc.com/category/financial-reports/\n \n \n \n Highlights\n \n \n \n ·\n Acquisition of Lyramid Pty Limited (\"Lyramid\") for £1 million (before adjustments), a combination of cash and shares via a Reverse Take Over\n \n \n ·\n Expert in molecular virology and cancer and a leading global expert on Midkine, Professor Graham Robertson joined Roquefort as Chief Scientific Officer from Lyramid\n \n \n ·\n Commencement of Lyramid's pre-clinical programme\n \n \n ·\n Fully funded to deliver drug candidate to clinical trials by H2 2023\n \n \n \n Post Period End Highlights\n \n \n \n ·\n Lead compounds identified for cancer programme\n \n \n ·\n Midkine patent filed following positive pe-clinical in vitro trials\n \n \n ·\n Significantly strengthened the Board with two highly experienced sector NED appointments\n \n \n ·\n Professor Trevor Jones appointment as advisor to the Board\n \n \n ·\n Cash at the bank as at 30 April 2022: £2.47 million\n \n \n \n Commenting on the Annual Results, Executive Chairman, Stephen West said:\n \n \"\n I am pleased to report the first annual results to shareholders as a biotech company. The Company has made significant progress as a biotech entity which culminated in the acquisition of Lyramid and its pre-clinical drug development programmes in December 2021. We believe Lyramid to be a clear market leader in Midkine inhibiting RNA therapeutic drugs with its exclusive worldwide licence to commercialise up to 37 patents for the treatment of cancer patients, autoimmune disorders, chronic kidney disease and Covid-19.\n \n \n Since the year-end we have made progress with our pre-clinical programme, and selected our most promising lead drug candidates in cancer. The Company then filed...